February 23rd 2024
Results of a study conducted by the National Institutes of Health indicate that the Paxlovid prevented a substantial number of hospitalizations associated with COVID-19.
February 20th 2024
Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.
February 12th 2024
The FDA granted accelerated approval to Elahere in November 2022 for adults with folate receptor-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies.
February 9th 2024
Key steps in relationship-building beyond just treatment options.
Nobel Laureate Elie Wiesel Exclusive Interview
Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?
Emerging Pharma Leaders 2010
Strong, skilled management is on the agenda as never before. Find out who made 2010's roster of high-potential change masters-and how they plan to lead the industry through the turbulent times ahead.
Brand of the Year: Avastin
As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.
Pharma Unplugged Episode #4 - Give Until It Hurts
GAO reviews price hikes in branded drugs, FDA opens up to public, and pharma opens its wallet for Haiti. All on this week's Pharma Unplugged.
Place Your Bets
The industry is a-changing. Here are eight seminal events that describe how.
Finance: Q&A with Annette Grimaldi
The latest dealmaking trends: Early-stage is back in favor. There's more money to be made in being acquired than in going public. And license deals are putting more on the back end.
2 Commerce Drive Cranbury, NJ 08512